Furthermore, in another study, ERCC1 protein status did not correlate with survival in stage IV NSCLC[46], while in a trial of customized cisplatin based on ERCC1 mRNA expression, response rate was 39% in the control arm and 50% in the customized arm (P = 0.02)[47]. The gene discussed is ERCC1; the disease is non-small cell lung carcinoma.